CN1278727A - 单胺氧化酶抑制剂和h5-ht1B拮抗剂或部分激动剂的组合 - Google Patents

单胺氧化酶抑制剂和h5-ht1B拮抗剂或部分激动剂的组合 Download PDF

Info

Publication number
CN1278727A
CN1278727A CN98811114A CN98811114A CN1278727A CN 1278727 A CN1278727 A CN 1278727A CN 98811114 A CN98811114 A CN 98811114A CN 98811114 A CN98811114 A CN 98811114A CN 1278727 A CN1278727 A CN 1278727A
Authority
CN
China
Prior art keywords
naphthyl
formula
methyl
combination
morpholinobenzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN98811114A
Other languages
English (en)
Chinese (zh)
Inventor
S·贝里
S·罗斯
S·O·托尔贝里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1278727A publication Critical patent/CN1278727A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN98811114A 1997-09-18 1998-09-09 单胺氧化酶抑制剂和h5-ht1B拮抗剂或部分激动剂的组合 Pending CN1278727A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE97033765 1997-09-18
SE9703376A SE9703376D0 (sv) 1997-09-18 1997-09-18 A new combination

Publications (1)

Publication Number Publication Date
CN1278727A true CN1278727A (zh) 2001-01-03

Family

ID=20408296

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98811114A Pending CN1278727A (zh) 1997-09-18 1998-09-09 单胺氧化酶抑制剂和h5-ht1B拮抗剂或部分激动剂的组合

Country Status (27)

Country Link
US (1) US6159970A (enExample)
EP (1) EP1014986B1 (enExample)
JP (1) JP2001516719A (enExample)
KR (2) KR20010024087A (enExample)
CN (1) CN1278727A (enExample)
AR (1) AR013503A1 (enExample)
AT (1) ATE270889T1 (enExample)
AU (1) AU752719B2 (enExample)
BR (1) BR9812236A (enExample)
CA (1) CA2302204A1 (enExample)
DE (1) DE69825062T2 (enExample)
DK (1) DK1014986T3 (enExample)
EE (1) EE200000146A (enExample)
ES (1) ES2222603T3 (enExample)
HU (1) HUP0100621A2 (enExample)
ID (1) ID25789A (enExample)
IL (1) IL134775A0 (enExample)
IS (1) IS5401A (enExample)
MX (1) MXPA00002616A (enExample)
NO (1) NO20001400L (enExample)
PL (1) PL339368A1 (enExample)
PT (1) PT1014986E (enExample)
SE (1) SE9703376D0 (enExample)
SK (1) SK2832000A3 (enExample)
TR (1) TR200000725T2 (enExample)
WO (1) WO1999013878A1 (enExample)
ZA (1) ZA987804B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110179988A (zh) * 2019-07-10 2019-08-30 王大伟 五羟色胺再摄取抑制剂和单胺氧化酶抑制剂联合在制备治疗抑郁症或早泄药物中的应用

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957948A (en) * 1988-05-05 1990-09-18 Interface, Inc. Biocidal protective coating for heat exchanger coils
SE9601110D0 (sv) 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
WO2002066454A1 (fr) * 2001-02-21 2002-08-29 Sankyo Company, Limited Derives de chromene
ES2323451T7 (es) * 2001-07-20 2011-08-01 Psychogenics Inc. Tratamiento para el trastorno de hiperactividad con deficit de atencion.
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US20090054453A1 (en) * 2006-03-17 2009-02-26 Lilian Alcaraz Novel Tetralins as 5-HT6 Modulators
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
SI2091948T1 (sl) 2006-11-30 2012-07-31 Probiodrug Ag Novi inhibitorji glutaminil ciklaze
EA200901140A1 (ru) 2007-03-01 2010-04-30 Пробиодруг Аг Новое применение ингибиторов глутаминилциклазы
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
CN102695546B (zh) 2009-09-11 2014-09-10 前体生物药物股份公司 作为谷氨酰胺酰环化酶抑制剂的杂环衍生物
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
SG183229A1 (en) 2010-03-10 2012-09-27 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
EP4633638A1 (en) * 2022-12-14 2025-10-22 Luminous Mind Inc. Treatment of psychological factors affecting other medical conditions (pfaomc)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
DE69232003T2 (de) * 1991-09-18 2002-04-25 Glaxo Group Ltd., Greenford Benzanilidderivate als 5-HT1D-Antagonisten
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110179988A (zh) * 2019-07-10 2019-08-30 王大伟 五羟色胺再摄取抑制剂和单胺氧化酶抑制剂联合在制备治疗抑郁症或早泄药物中的应用

Also Published As

Publication number Publication date
US6159970A (en) 2000-12-12
DE69825062D1 (de) 2004-08-19
SK2832000A3 (en) 2000-09-12
CA2302204A1 (en) 1999-03-25
NO20001400L (no) 2000-05-05
NO20001400D0 (no) 2000-03-17
SE9703376D0 (sv) 1997-09-18
ZA987804B (en) 1999-03-18
HUP0100621A2 (hu) 2001-08-28
ES2222603T3 (es) 2005-02-01
AU752719B2 (en) 2002-09-26
EP1014986A1 (en) 2000-07-05
JP2001516719A (ja) 2001-10-02
MXPA00002616A (es) 2002-04-24
DK1014986T3 (da) 2004-10-25
IS5401A (is) 2000-03-14
EE200000146A (et) 2001-02-15
ID25789A (id) 2000-11-02
ATE270889T1 (de) 2004-07-15
AR013503A1 (es) 2000-12-27
PT1014986E (pt) 2004-10-29
EP1014986B1 (en) 2004-07-14
KR20010024084A (ko) 2001-03-26
PL339368A1 (en) 2000-12-18
BR9812236A (pt) 2000-07-18
KR20010024087A (ko) 2001-03-26
IL134775A0 (en) 2001-04-30
TR200000725T2 (tr) 2000-08-21
DE69825062T2 (de) 2005-08-25
AU9193198A (en) 1999-04-05
WO1999013878A1 (en) 1999-03-25

Similar Documents

Publication Publication Date Title
CN1278727A (zh) 单胺氧化酶抑制剂和h5-ht1B拮抗剂或部分激动剂的组合
CN1240701C (zh) 用作5HT2C激动剂的2,3,4,4a-四氢-1H-吡嗪并(1,2-a)喹喔啉-5(6H)酮衍生物
CN1195519C (zh) 5-HT再摄取抑制剂与h5-HT1B拮抗剂或部分激动剂的组合物
CN1036652C (zh) 碱式季酰胺,其制备方法及其药物组合物
CN1034072C (zh) 四氢咔唑衍生物的制备方法
CN1257892C (zh) 新的具有5-ht6受体亲和性的吲哚衍生物
CN1172919C (zh) 芳烷醇哌嗪衍生物及其在制备抗抑郁症药物中的应用
CN87100040A (zh) 二芳基烷基取代的烷基胺、其制备工艺方法、应用以及含有该类化合物的药物
CN1391561A (zh) 喹唑啉化合物和含有喹唑啉化合物的药物组合物
CN1167681C (zh) 稠合二氢吲哚衍生物及其作为5ht特别是5ht2c受体配体的用途
CN1805938A (zh) 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
CN1073101C (zh) 取代的1,2,3,4-四氢化萘衍生物
CN1753895A (zh) 螺环取代的吡咯并嘧啶化合物
CN1034918A (zh) 化学化合物
CN1675189A (zh) 苯并噻唑衍生物的新用途
CN1093859C (zh) 新型吲哚-2,3-二酮-3-肟衍生物
CN100339379C (zh) 2-吡啶基-6,7,8,9-四氢嘧啶并[1,2-а]嘧啶-4-酮和7-吡啶基-2,3-二氢咪唑并[1,2-а]嘧啶-5(1H)酮衍生物
HK1040055A1 (en) Use of olanzapine and fluoxetine in the preparation of a medicament for the treatment of treatment resistant major depression
CN1111986A (zh) 治疗肠应激综合症的异噁唑衍生物
CN1117092C (zh) 氮杂双环化合物,其药物组合物及医药用途
CN1107158A (zh) 多取代的2-氨基-噻唑衍生物
CN1278809A (zh) 取代的苯并二氢吡喃衍生物
CN1105358A (zh) N-取代氨杂双环庚烷衍生物,其制备方法以及用途
CN1054249A (zh) 磺酰苯胺衍生物及其在医药上的应用
CN1151165A (zh) 三萜衍生物及其药用组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication